Online inquiry

IVTScrip™ mRNA-Anti-NGF, AMG-403(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) (CAT#: GTTS-WQ2840MR)

This product GTTS-WQ2840MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets NGF gene. The antibody can be applied in Osteoarthritis (OA) research.

Specifications
Product type	mRNA
Modified bases	5-Methyl-CTP
5' Cap	Cap 1
Species	Homo sapiens
RefSeq	NM_001194950.1
Applications	Gene therapy research
Format	Powder
Quantity	100 µg
Purification	oligo-dT affinity purification

Target Gene
Gene ID	403402
UniProt ID	F1PDQ3

Download
Download resources about mRNA therapeutics development to boost your research.

CUSTOMER REVIEWS and Q&As
There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-NGF, AMG-403(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ2840MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT	Product Name	Product Type	CDs
GTTS-WQ6204MR	IVTScrip™ mRNA-Anti-RABVgp4, CR4098(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))	mRNA	CR4098
GTTS-WQ3997MR	IVTScrip™ mRNA-Anti-PDCD1, BGB-A317(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))	mRNA	BGB-A317
GTTS-WQ9236MR	IVTScrip™ mRNA-Anti-MUC1, IMMU-107(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))	mRNA	IMMU-107
GTTS-WQ15492MR	IVTScrip™ mRNA-Anti-FCGRT, UCB-7665(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))	mRNA	UCB-7665
GTTS-WQ7213MR	IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-G4h-28-F9Z-TpERt CAR(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))	mRNA	FMC63 scFv-G4h-28-F9Z-TpERt CAR
GTTS-WQ12682MR	IVTScrip™ mRNA-Anti-FZD1&FZD2&FZD5&FZD7&FZD8, OMP-18R5(Cap 1, Pseudo-UTP, 120 nt-poly(A))	mRNA	OMP-18R5
GTTS-WQ526MR	IVTScrip™ mRNA-Anti-CD40, 4D11(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))	mRNA	4D11
GTTS-WQ2632MR	IVTScrip™ mRNA-Anti-IL2RB, AMG 592(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))	mRNA	AMG 592

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST